AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03085953 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: Control group will receive training following all measurements points to serve as a comparison group
Study NCT03246412 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nevus doctor clinical decision support
Description: The computer program analyzes dermatoscopic images. The output is an estimate of the risk of the skin lesion representing skin cancer. The decision support tool helps the doctor to assess the significance of the computer output by taking into account clinical information.
Study NCT00879398 — intervention group
Intervention type: DRUG
Intervention: Toviaz treatment
Description: 4 mg starting then can be followed by 8 mg
Study NCT02082379 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: inhaled normal saline using different interfaces.
Description: A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The infants will be videotape while they receive inhaled aerosol, and sound will be captured. The camera will be positioned so the face of the parent holding the child will not be visible.
Study NCT01799135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DCE-MRI scan
Study NCT01799135 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Study NCT01770496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Childhood vaccination reminder / recall notification
Study NCT04289623 — intervention group
Intervention type: BEHAVIORAL
Intervention: Email
Description: Email
Study NCT04289623 — intervention group
Intervention type: BEHAVIORAL
Intervention: Loss frame
Description: Email
Study NCT04289623 — intervention group
Intervention type: BEHAVIORAL
Intervention: Testimonial (medical expert)
Description: Email
Study NCT04289623 — intervention group
Intervention type: BEHAVIORAL
Intervention: Testimonial (rank-and-file)
Description: Email
Study NCT04289623 — intervention group
Intervention type: BEHAVIORAL
Intervention: Social norms (percentage)
Description: Email
Study NCT04289623 — intervention group
Intervention type: BEHAVIORAL
Intervention: Social norms (number)
Description: Email
Study NCT04185948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet guidelines plus intermittent fasting
Description: For 4 weeks participants will be encouraged to adopt the Mediterranean dietary guidelines as recommended by the Mediterranean Diet Foundation in Barcelona, Spain. In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
Study NCT04185948 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UK Eatwell guidelines plus intermittent fasting
Description: For 4 weeks participants will be encouraged to adopt the UK dietary guidelines (Eatwell Guide). In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
Study NCT02700113 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Intervention is not a part of this study. This is a behavioral phenotyping study of minimally verbal individuals with Autism Spectrum Disorder.
Study NCT03758443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 Dose A
Description: See Arm description
Study NCT03758443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 Dose B
Description: See Arm description
Study NCT03758443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 Dose C
Description: See Arm description
Study NCT03758443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See Arm description
Study NCT01951222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0162
Study NCT01951222 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01224964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast, 10 mg
Study NCT01224964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: long acting beta2 mimetic
Description: ICS+long acting beta2 agonist: twice daily
Study NCT00199875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)
Description: Patients received a single infusion of \^90Y-DOTA-cG250, with escalating doses administered to sequentially enrolled cohorts until MTD determination.
Study NCT00887874 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Subject will only fill out a questionaire when entering the observational study.
Study NCT00408460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO
Study NCT00408460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT03617185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Training (HIIT)
Description: Patients will complete a HIIT training protocol of a total of 10 x 1 min intervals at 90% heart rate (HR) max. They will continue this training protocol, 3 sessions a week (2 supervised and 1 unsupervised), for 24 months.
Study NCT03617185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Exercise
Description: Patients will receive counseling regarding exercise as a routine part of their participation in the bariatric surgery clinic. Specifically, they are counseled to participate in 60 min of aerobic exercise daily in addition to 2-3 non-consecutive days of strength training workouts every wk. Patients are encouraged to contact the bariatric conditioning program, obtain a gym membership, purchase exercise equipment, join a walking group, and/or sign up for fitness classes (employer or city parks and recreation).
Study NCT04356755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AdMSC
Description: At day 0, patients will have AdMSC injections in their ischemic DU. Patients will be followed-up for 16 weeks
Study NCT04356755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At day 0, patients will have placebo injections in their ischemic DU. Patients will be followed-up for 16 weeks
Study NCT03400696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower carbohydrate diet
Description: Focused on limiting dietary carbohydrates, eating healthy fat and protein sources, and engaging in physical activity
Study NCT03400696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Higher fiber diet
Description: Focused on increasing dietary fiber, lowering fat intake from animal sources, and engaging in physical activity
Study NCT03400696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity focused
Description: Focused on aerobic and resistance exercise, while following dietary guidelines \<https://www.choosemyplate.gov>
Study NCT02196142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortisol 20mg
Description: Drug: Cortisol 20mg
Study NCT01011556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Teriparatide
Description: Administered transdermally, applied once daily for 6 hours over 12 months
Study NCT02396290 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fractional carbon dioxide laser with platelet rich plasma
Description: fractional carbon dioxide laser followed by platelet rich plasma injection
Study NCT02396290 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fractional carbon dioxide laser with NS
Description: fractional carbon dioxide laser followed by normal saline injection
Study NCT03617185 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Patients will undergo bariatric surgery as part of their routine care
Study NCT03868306 — intervention group
Intervention type: OTHER
Intervention: CBC , Iron study and Haemoglobin electrophoresis .
Description: The study will conducting on 100 patients of microcytic hypochromic anaemia who recruited from the hematology outpatient clinic , Assiut University Children Hospital . Beside history and clinical examination , the studied cases will be subjected to the following investigations Complete blood count ( CBC ) with comparison of MCV , RBCs count , RDW and RDWI . Determination of serum ferritin , serum iron and total iron bending capacity ( TIBC ) . HB electrophoresis . Patient with HBA2 more than 3.2 % are identified as beta thalassemia trait and patients with serum ferritin less than 12 ng / ml are identified as IDA cases. Validity of both discrimination indices are evaluated by calculating there sensitivity , specificity , positive predictive value , negative predictive value and Youden index ( YI ) Based on statistical criteria in ideal test should have high sensitivity and specificity and Youden index.
Study NCT01799135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4D-CT scan
Study NCT03014115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: combination ARA + DHA
Description: combination ARA + DHA supplemented infant formula
Study NCT00145613 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem Cell Transplantation
Description: An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
Study NCT00145613 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Miltenyi Biotec CliniMACS
Description: stem cell selection device
Study NCT00145613 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Systemic chemotherapy and antibodies
Description: Transplant recipients received a non-TBI based reduced intensity conditioning regimen consisting of OKT-3, Fludarabine Thiotepa, and Melphalan. Rituximab was administered within 24 hours of the transplant in an effort to prevent PTLPD. In addition to T-cell depletion of the haploidentical stem cell product, Mycophenolate mofetil was provided as prophylaxis for GVHD.
Study NCT01236417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercising block
Description: Exercising for 8 weeks using an elastic band
Study NCT03014115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA
Description: DHA supplemented infant formula
Study NCT03563079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: Soft Tissue Mobilization
Study NCT03563079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Myofascial Release
Description: Myofascial Release Technique
Study NCT03317873 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Testmeal A
Description: The tesmeal A is is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
Study NCT02666924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chinese-canadian specific cooking classes
Description: Series of four, four-hour cooking classes, occurring monthly for four months. Each of the cooking classes in the series will have diabetes self-management learning objectives: food choices, meal planning and preparation, portion control, self-monitoring of blood glucose levels and physical activity.
Study NCT02666924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes educational classes
Description: Series of two, four-hour diabetes education classes, occurring weekly for two weeks. Each class is run by a registered dietitian and nurse, trained as clinical diabetes educators, as per standards of the canadian diabetes association. Classes include focused teaching of the background of diabetes, dietary recommendations for diabetes, lifestyle recommendations for diabetes, medications for diabetes, and general standard of living recommended for diabetes mellitus type 2.
Study NCT01359579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varespladib methyl
Description: Single oral 500 mg dose
Study NCT03616002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hookah smoking
Description: ad lib hookah smoking for 30 minutes in a controlled laboratory environment.
Study NCT00779220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravenous repeating dose
Study NCT00779220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: Oral repeating dose
Study NCT00779220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Oral repeating dose
Study NCT00779220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocrelizumabu 50mg
Description: Intravenous repeating dose (50mg)
Study NCT00779220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocrelizumabu 200mg
Description: Intravenous repeating dose (200mg)
Study NCT00779220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocrelizumab 500mg
Description: Intravenous repeating dose (500mg)
Study NCT03429049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975-05
Description: Receiving CNTX-4975-05 injection
Study NCT03429049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Receiving Placebo injection
Study NCT01216410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Prophylactic Metoclopramide 10 mg given before spinal together with prophylactic phenylephrine infusion
Study NCT05073978 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any intervention
Study NCT01672008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-100
Study NCT03402113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: consistent infusion at a loading dose of 0.15ug/kg/h, increased by 0.15ug/kg/h, with a maximum dose of 1.5ug/kg/h.
Study NCT03402113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: consistent infusion at a loading dose of 1mg/h, increased by 1mg/h, with a maximum dose of 10mg/h.
Study NCT02256592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota
Description: 300 mL of fecal suspension from a healthy donor will be delivered during colonoscopy
Study NCT00860288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Study NCT00860288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Study NCT00860288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT00860288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT00860288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00860288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Study NCT00492531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Oral Sildenafil 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
Study NCT00492531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
Study NCT03775330 — intervention group
Intervention type: RADIATION
Intervention: Stereotactic Radiosurgery (SRS)
Description: SRS or hypofractionated stereotactic radiation delivered via the Leksell Gammknife Perfexion/Icon radiosurgery system. Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions or 24-27 Gy in 3 fractions at the discretion of the radiation oncologist~Maximum diameter of metastasis (doses in single fraction):~≤ 2 cm: 15-20 Gy > 2 cm and ≤ 3 cm: 15-18 Gy > 3 cm and ≤ 4 cm: 15 Gy~Tumour location (doses in single fraction):~Brainstem: 15 Gy~Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions may be used for lesions > 2 cm at the discretion of the radiation oncologist~Note: SRS dosing reduced by 20% (for all prescriptions > 15 Gy) when patient is randomized to SRS + WBRT arm
Study NCT03775330 — intervention group
Intervention type: RADIATION
Intervention: Whole brain radiation (WBRT)
Description: WBRT 20 Gy in 5 fractions or 30 Gy in 10 fractions at the discretion of the radiation oncologist
Study NCT03022435 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: TIV
Description: Influenza Virus Vaccine Suspension for Intramuscular Injection
Study NCT03022435 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: High-Dose TIV
Description: High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe
Study NCT03022435 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: LAIV
Description: Live, attenuated influenza vaccine for Intranasal Spray
Study NCT02328417 — intervention group
Intervention type: OTHER
Intervention: Consecutive radical cystectomies
Description: Pre-, intra- and post-operative clinical measures during radical cystectomy clinical process
Study NCT02824237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Improved cook stove
Description: The investigators will conduct a pre-post intervention study to evaluate effectiveness of improved stoves and compare outcomes after two years
Study NCT04652427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride 0.1 MG/ML
Description: At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
Study NCT04652427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
Study NCT02399371 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02399371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02399371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies
Study NCT00237172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: once daily
Study NCT00885287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Description: Standard treatment-dose of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria according to national treatment guidelines
Study NCT04154930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane-L®
Description: Intradermal injection.
Study NCT05654935 — intervention group
Intervention type: RADIATION
Intervention: Ultrasound for Carotid Arteries
Description: Cohort A: each subject will undergo two manual ultrasound image acquisitions by two different registered vascular sonographers who will be blinded to one another's images and findings.~Cohort B: each subject in Cohort B will undergo one manual ultrasound acquisition conducted at Rush University Medical Center.
Study NCT05654935 — intervention group
Intervention type: RADIATION
Intervention: Telerobotic Ultrasound for Carotid Arteries
Description: Cohort A: each subject will undergo two separate telerobotic acquisitions, in which the robotic arm will be controlled by two separate sonographers from Mount Sinai Medical Center (New York, NY). The sonographers controlling the robotic arm will be blinded to one another's images and to the images from the manual acquisition.~Cohort B: each subject will undergo one telerobotic ultrasound (in random sequence with the manual acquisition also performed for this cohort) acquired by a separate technologist than the technologist that acquired the subject's manual ultrasound. This acquisition will be conducted at Rush University Medical Center by a technologist blinded to the images of the manual acquisition technologist. Robotic acquisition will be manipulated from a different building at Rush University Medical Center using a broadband cellular internet signal (rather than the institutional intranet).
Study NCT01272973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Semaglutide (oral) administered once daily for 10 weeks.Individually adjusted dose investigated up to maximum level.
Study NCT01272973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo (oral) administered once daily for 10 weeks.
Study NCT00608933 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Patients complete questionnaires
Study NCT00608933 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: questionnaire administration
Description: Patients complete questionnaires